We are a vibrant young company committed to science first. Our mission is to develop and deliver the unprecedented accuracy of TwinStrand Duplex Sequencing™ technology for applications in clinical medicine and life sciences where it can do the greatest good for the greatest number of people. Our approach is multifaceted and encompasses internal development projects, external collaborations and empowering of partner organizations.
TwinStrand Duplex Sequencing™ technology is an ultra-high accuracy, error-corrected sequencing method that overcomes the limitations of NGS by independently tracking both strands of individual DNA molecules. Utilizing our multi-patented novel chemistry and cloud-based bioinformatics, the paired sequences are compared to eliminate errors, reducing error rates from 1-in-100 to 1-in-10 million, revealing ultra-low frequency variants.
TwinStrand Duplex Sequencing™ technology is an ultra-high accuracy, error-corrected sequencing method that overcomes the limitations of NGS by independently tracking both strands of individual DNA molecules. Utilizing our multi-patented novel chemistry and cloud-based bioinformatics, the paired sequences are compared to eliminate errors, reducing error rates from 1-in-100 to 1-in-10 million, revealing ultra-low frequency variants.
Employees: 51-200
Total raised: $66M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | S32 | s32.com |
| - | Madrona Ve... | madrona.co... |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.05.2021 | Series B | $50M | - |
| 07.01.2020 | Series A | $16M | - |
Mentions in press and media 10
| Date | Title | Description |
| 07.10.2022 | TwinStrand CEO and co-founder steps down from Seattle biotech startup amid reported layoffs | Jesse Salk, co-founder of TwinStrand. (TwinStrand Photo) TwinStrand Biosciences’ co-founder Jesse Salk has stepped down from the CEO role, according to a statement issued by the Seattle biotech company Friday. Salk will remain as chief scie... |
| 10.05.2021 | TwinStrand Biosciences lands $50M | TwinStrand Biosciences, a genomics startup developing technology to identify ultra-low frequency DNA mutations, has raised a $50 million Series B led by Section 32. New investors Soleus Capital and Janus Henderson Investors, as well as exis... |
| 07.05.2021 | TwinStrand Biosciences Inks $50M Series B | SEATTLE, WA, TwinStrand Biosciences has closed a $50 million Series B financing led by Section 32. >> Click here for more funding data on TwinStrand Biosciences >> To export TwinStrand Biosciences funding data to PDF and Exc... |
| 06.05.2021 | TwinStrand Biosciences : Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and Accuracy | TwinStrand Biosciences, the pioneer and developer of Duplex Sequencing, an ultra-high accuracy technology for revealing exceptionally low-frequency genetic variants, today announced that it has closed a $50 million Series B financing led by... |
| 06.05.2021 | Grandson of Jonas Salk raises cash to find ‘genetic needles in the haystack’ | Jesse Salk, CEO and co-founder of TwinStrand Biosciences. (TwinStrand Photo) New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, t... |
| 06.05.2021 | TwinStrand Biosciences raises $50M to increase adoption of DNA sequencing tech for cancer detection | While much of the world is still getting on board with next-generation sequencing technology, many biotech developers are already in hot pursuit of the next next-generation tools. One such developer is TwinStrand Biosciences. The Seattle-ba... |
| 16.01.2020 | Seattle-Based TwinStrand Biosciences Raises $16 Million | Novel genetic sequencing technology company TwinStrand Biosciences announced it has raised $16 million in Series A funding TwinStrand Biosciences — a novel genetic sequencing technology company — announced it has closed $16 million in Serie... |
| 07.01.2020 | TwinStrand Biosciences Raises $16M in Series A Funding | TwinStrand Biosciences, a Seattle, WA-based novel genetic sequencing technology company, closed a $16m Series A funding, including $12m in new capital. The round was led by Madrona Venture Group with participation from Alexandria Venture In... |
| 30.08.2018 | University of Washington spin-out raising cash for more accurate DNA sequencing technology | BigStock Photo TwinStrand Biosciences, a spin-out of the University of Washington, is raising cash to commercialize DNA sequencing technology that it says can detect tiny genetic mutations invisible to current sequencers. According to an SE... |
| - | TwinStrand Biosciences | “TwinStrand Biosciences - An end-to-end solution, from pre-sequencing biochemistry to post-sequencing bioinformatics.” |